PDF(Pubmed)
Abstract：
The purpose of this study was to precisely evaluate the serum Dickkopf-1 (DKK-1) level in patients with ankylosing spondylitis (AS) relative to that in normal controls and to test the causal relationship between DKK-1 and the risk of AS.
Embase, PubMed, Web of Science, WANFANG DATA, VIP, and China National Knowledge Infrastructure (CNKI) were comprehensively searched until July 2022 for pertinent studies. The pooled standardized mean difference (SMD) with a 95% confidence interval (CI) was calculated by the fixed or random-effect model. In Mendelian randomization (MR) analysis on the causal relationship between serum DKK-1 level and AS risk, the inverse variance weighting method (IVW), MR-Egger regression, weighted median method, and weighted pattern method were applied. Sensitivity analyses, including the horizontal pleiotropy test, heterogeneity test, and leave-one-out test, were also performed.
The meta-analysis of 40 studies containing 2,371 AS patients and 1,633 healthy controls showed that there was no significant difference in DKK-1 serum level between AS patients and normal controls (pooled SMD=0.207, 95% CI =-0.418-0.832, P=0.516). The subgroup analysis of the CRP ≤ 10 mg/L group showed that AS patients had higher serum DKK-1 concentration than the healthy controls (SMD=2.267, 95% CI = 0.102-4.432, P=0.040). Similarly, MR analysis also demonstrated no significant association between DKK-1 serum level and AS (IVW OR=0.999, 95% CI = 0.989-1.008, P=0.800). All sensitivity analyses revealed consistent results.
There was no significant change in serum DKK-1 concentration between AS patients and healthy controls. In addition, no causal relationship exists between serum DKK-1 levels and AS risk.
Embase, PubMed, Web of Science, WANFANG DATA, VIP, and China National Knowledge Infrastructure (CNKI) were comprehensively searched until July 2022 for pertinent studies. The pooled standardized mean difference (SMD) with a 95% confidence interval (CI) was calculated by the fixed or random-effect model. In Mendelian randomization (MR) analysis on the causal relationship between serum DKK-1 level and AS risk, the inverse variance weighting method (IVW), MR-Egger regression, weighted median method, and weighted pattern method were applied. Sensitivity analyses, including the horizontal pleiotropy test, heterogeneity test, and leave-one-out test, were also performed.
The meta-analysis of 40 studies containing 2,371 AS patients and 1,633 healthy controls showed that there was no significant difference in DKK-1 serum level between AS patients and normal controls (pooled SMD=0.207, 95% CI =-0.418-0.832, P=0.516). The subgroup analysis of the CRP ≤ 10 mg/L group showed that AS patients had higher serum DKK-1 concentration than the healthy controls (SMD=2.267, 95% CI = 0.102-4.432, P=0.040). Similarly, MR analysis also demonstrated no significant association between DKK-1 serum level and AS (IVW OR=0.999, 95% CI = 0.989-1.008, P=0.800). All sensitivity analyses revealed consistent results.
There was no significant change in serum DKK-1 concentration between AS patients and healthy controls. In addition, no causal relationship exists between serum DKK-1 levels and AS risk.
摘要：
本研究的目的是准确评估强直性脊柱炎（AS）患者血清Dickkopf-1（DKK-1）相对于正常对照组的水平，并检验DKK-1与风险之间的因果关系。AS。
Embase,PubMed,WebofScience,万方数据,VIP,和中国国家知识基础设施(CNKI)进行了全面搜索，直到2022年7月进行相关研究。通过固定或随机效应模型计算具有95％置信区间（CI）的合并标准化平均差（SMD）。在孟德尔随机化（MR）分析血清DKK-1水平与AS风险之间的因果关系，方差逆加权法(IVW)，MR-Egger回归，加权中位数法，采用加权模式法。敏感性分析，包括水平多效性测试，异质性检验，和离开一次测试，也表演了。
对包含2,371例AS患者和1,633例健康对照者的40项研究的荟萃分析显示，AS患者与正常对照者血清DKK-1水平无显著差异(SMD=0.207，95%CI=-0.418-0.832，P=0.516)。CRP≤10mg/L组患者血清DKK-1浓度高于健康对照组（SMD=2.267，95%CI=0.102～4.432，P=0.040）。同样，MR分析还显示DKK-1血清水平与AS之间没有显着关联（IVWOR=0.999，95％CI=0.989-1.008，P=0.800）。所有敏感性分析都显示出一致的结果。
AS患者与健康对照组之间血清DKK-1浓度无明显变化。此外,血清DKK-1水平与AS风险之间无因果关系.
Embase,PubMed,WebofScience,万方数据,VIP,和中国国家知识基础设施(CNKI)进行了全面搜索，直到2022年7月进行相关研究。通过固定或随机效应模型计算具有95％置信区间（CI）的合并标准化平均差（SMD）。在孟德尔随机化（MR）分析血清DKK-1水平与AS风险之间的因果关系，方差逆加权法(IVW)，MR-Egger回归，加权中位数法，采用加权模式法。敏感性分析，包括水平多效性测试，异质性检验，和离开一次测试，也表演了。
对包含2,371例AS患者和1,633例健康对照者的40项研究的荟萃分析显示，AS患者与正常对照者血清DKK-1水平无显著差异(SMD=0.207，95%CI=-0.418-0.832，P=0.516)。CRP≤10mg/L组患者血清DKK-1浓度高于健康对照组（SMD=2.267，95%CI=0.102～4.432，P=0.040）。同样，MR分析还显示DKK-1血清水平与AS之间没有显着关联（IVWOR=0.999，95％CI=0.989-1.008，P=0.800）。所有敏感性分析都显示出一致的结果。
AS患者与健康对照组之间血清DKK-1浓度无明显变化。此外,血清DKK-1水平与AS风险之间无因果关系.
